Subchronic treatment with methamphetamine and phencyclidine differentiallyalters the adenosine A(1) and A(2A) receptors in the prefrontal cortex, hippocampus, and striatum of the rat

Shirayama, Y Hashimoto, K Higuchi, T Minabe, Y

Y. Shirayama et al., Subchronic treatment with methamphetamine and phencyclidine differentiallyalters the adenosine A(1) and A(2A) receptors in the prefrontal cortex, hippocampus, and striatum of the rat, NEUROCHEM R, 26(4), 2001, pp. 363-368

43

INGLESE

Article

Neurosciences & Behavoir

NEUROCHEMICAL RESEARCH

0364-3190 → ACNP

26

4

2001

363 - 368

ISI

0364-3190(200104)26:4<363:STWMAP>2.0.ZU;2-G

Subchronic treatment with MAP (4.6 mg/kg, i.p., once daily for 11 days) sig nificantly decreased the K-d, but not B-max, values of [H-3]1,3-dipropyl-8- cyclopentylxanthine ([H-3]DPCPX) binding to adenosine A(1) receptors in the prefrontal cortex and hippocampus, but not striatum, of rat brain. However , subchronic treatment with PCP (10 mg/kg, i.p., once daily for 11 days) di d not alter the K-d and B-max values of [H-3]DPCPX binding to adenosine A(1 ) receptors in these three regions. Subchronic treatment with MAP or PCP di d not alter the B-max and K-d values of [H-3]2-p-(2-carboxyehyl)phenethylam ino-5'-N-ethylcarboxyamidoadenosine ([H-3]CGS21680) binding to adenosine A( 2A) receptors in the striatum. Furthermore, subchronic treatment with MAP o r PCP significantly decreased the specific binding of [H-3]CGS21680 to aden osine A(2A) receptors in the hippocampus, but not in the prefrontal cortex. Thus, these results suggest that MAP and PCP may produce differential effe cts on the adenosine A(2A) receptors, but not adenosine A(1) receptors in r at brain.